Renovo CEO bullish on partnership prospects

Mark Ferguson, the CEO of the UK's Renovo Group, says the company is getting closer to a licensing deal for its lead product, an anti-scarring therapy. Renovo has gathered positive data on Juvista from four mid-stage trials and Ferguson expects to announce a partner for the program by April, the first anniversary of its IPO. Juvista is injected into wounds following surgery and the company's broker has touted the therapy as a potential blockbuster. Final data should be submitted in 2009 and Renovo also expects to keep to its timetable to file for approval of Zesteem in 2008.

- here's the AFX report on Renovo

ALSO: Renovo has released more positive data from one of its Phase II trials of Juvista. Report

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.